Journal article
Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
Cancer medicine (Malden, MA), Vol.9(15), pp.5406-5415
08/2020
DOI: 10.1002/cam4.3229
PMID: 32519420
Abstract
Background Gemcitabine (GEM) plus nab-paclitaxel (NabP) (GEM 1000 mg/m(2) IV over 30 minutes + NabP 125 mg/m(2) IV given days 1, 8, and 15 every 28 days) is one of the two standard of care combination therapies for metastatic pancreatic ductal adenocarcinoma (PDAC). Our cancer center has utilized GEM-NabP given every two-weeks due to tolerability and patient convenience. Here, we review the safety and efficacy of this modified regimen.
Methods Metastatic PDAC patients (pts) who initiated front-line or second-line GEM-NabP during 2013-2017 were retrospectively reviewed. Primary objective was overall survival. Secondary objectives were disease control rate, progression-free survival, and the incidence of dose delays and/or adjustments.
Results From a total of 235 patients, 140 pts received GEM-NabP front-line while 95 pts received GEM-NabP second-line. Median dosing was 600 mg/m(2) at fixed-dose rate for GEM and 125 mg/m(2) for NabP given predominantly (similar to 90%) every two-weeks. Eastern Cooperative Group performance status of 0 and 1 pts had front-line OS of 12.7 and 9.6 months and when given second-line had OS of 8 months and 7.3 months, respectively. ECOG 0 and 1 pts had front-line progression-free survival (PFS) of 5.3 months and 2.8 months and second-line PFS was 3.5 months and 2.4 months, respectively. Treatment was well tolerated with limited dose modifications.
Conclusion Our analysis revealed safety with every two-week low dose GEM-NabP while maintaining efficacy. Patient schedule convenience should factor into metastatic incurable malignancies. We suggest the use of every two-week GEM-NabP particularly in patients desiring a modified schedule.
Details
- Title: Subtitle
- Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
- Creators
- Jane E. Rogers - The University of Texas MD Anderson Cancer CenterJonathan D. Mizrahi - The University of Texas MD Anderson Cancer CenterLianchun Xiao - The University of Texas MD Anderson Cancer CenterChirayu Mohindroo - The University of Texas MD Anderson Cancer CenterRachna T. Shroff - The University of Texas MD Anderson Cancer CenterRobert Wolff - The University of Texas MD Anderson Cancer CenterGauri R. Varadhachary - The University of Texas MD Anderson Cancer CenterMilind M. Javle - The University of Texas MD Anderson Cancer CenterMichael Overman - The University of Texas MD Anderson Cancer CenterDavid R. Fogelman - The University of Texas MD Anderson Cancer CenterKanwal P. S. Raghav - Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USAShubham Pant - The University of Texas MD Anderson Cancer CenterFlorencia McAllister - The University of Texas MD Anderson Cancer Center
- Resource Type
- Journal article
- Publication Details
- Cancer medicine (Malden, MA), Vol.9(15), pp.5406-5415
- DOI
- 10.1002/cam4.3229
- PMID
- 32519420
- ISSN
- 2045-7634
- eISSN
- 2045-7634
- Publisher
- Wiley
- Number of pages
- 10
- Grant note
- V Foundation MDACC K12CA088084-16A1 / Paul Calabresi K12 (NCI grant) Sabin Family Foundation AGA Foundation
- Language
- English
- Date published
- 08/2020
- Academic Unit
- Internal Medicine
- Record Identifier
- 9985177931602771
Metrics
1 Record Views